9 completed, 2 withdrawn, 1 terminated. 5 Phase 1, 4 Phase 3, 2 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Terminated 1, Withdrawn 1 |
| Phase 3 | 4 | Completed 4 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 4 | 1 | Completed 1 |
Follow VBI Vaccines Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PREHEVBRIO Pregnancy Outcomes Registry Data collection - Vaccine Exposure During Pregnancy | Withdrawn | VBI Vaccines Inc. | 2023-11-30 | 2026-05-11 | ||
| Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901e With E6020 Adjuvant VBI-2901e - COVID-19, Coronavirus Infections | Phase 1 | Withdrawn | VBI Vaccines Inc. | 2023-03-01 | 2023-04-04 | |
| Safety, Tolerability, and Immunogenicity of Trivalent Coronavirus Vaccine Candidate VBI-2901a VBI-2901a - COVID-19, Coronavirus Infections | Phase 1 | Completed | VBI Vaccines Inc. | 103 | 2022-10-05 | 2026-05-11 |
| Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) Infection BRII-835 (VIR-2218), BRII-179 (VBI-2601) with IFN-α, BRII-179 (VBI-2601) - Hepatitis B, Chronic | Phase 2 | Completed | Brii Biosciences Limited | 91 | 2021-04-12 | 2026-07-23 |
| Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidates VBI-2902a and VBI-2905a VBI-2902a, Placebo, VBI-2905a - Covid19 | Phase 1 | Completed | VBI Vaccines Inc. | 114 | 2021-03-15 | 2024-05-17 |
| Lot-to-lot Consistency of Sci-B-Vac™ in Adults Hepatitis B Vaccination - Hepatitis B Vaccines | Phase 3 | Completed | VBI Vaccines Inc. | 2838 | 2017-12-14 | 2021-03-25 |
| Immunogenicity and Safety of Sci-B-Vac® to Engerix-B® in Adults Hepatitis B Vaccination - Hepatitis B Vaccines | Phase 3 | Completed | VBI Vaccines Inc. | 1607 | 2017-12-13 | 2020-07-17 |
| Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects VBI-1901, Carmustine, Lomustine - Glioblastoma Multiforme | Phase 1 / Phase 2 | Terminated | VBI Vaccines Inc. | 70 | 2017-12-06 | 2026-05-08 |
| Study to Evaluate Safety, Tolerability, and Immunogenicity of Candidate Human Cytomegalovirus Vaccine in Healthy Adults VBI-1501A 0.5 μg, VBI-1501A 1.0 μg, VBI-1501A 2.0 μg - Cytomegalovirus Infections | Phase 1 | Completed | VBI Vaccines Inc. | 128 | 2016-06-23 | 2020-04-20 |
| A Study to Qualify an In-house Reference Standard Batch of Sci-B-Vac™ Sci-B-Vac™ - Hepatitis B | Phase 4 | Completed | VBI Vaccines Inc. | 91 | 2015-11-01 | 2022-06-24 |
| Safety and Immunogenicity of Recombinant Hepatitis B Vaccine Sci-B-Vac® Compared to Engerix-B® Sci-B-Vac®, Engerix-B® - Hepatitis B | Phase 3 | Completed | VBI Vaccines Inc. | 100 | 2014-04-18 | 2022-07-25 |
| A Bridging Study: Comparing Two Lots of Sci-B-Vac™ and Engerix-B in Healthy Adults Sci-B-Vac-Lot B, Sci-B-Vac-Lot A, Engerix-B - Hepatitis B | Phase 3 | Completed | VBI Vaccines Inc. | 402 | 2006-03-02 | 2022-07-26 |
Hepatitis B (7) · COVID-19 (3) · Coronavirus Infections (2) · Severe Acute Respiratory Syndrome (2) · Cytomegalovirus Infections (1) · Glioblastoma (1) · Hepatitis (1) · Hepatitis B, Chronic (1) · Herpesviridae Infections (1) · Neoplasms (1) · Virus Diseases (1)
Pre-S vaccine (3) · Engerix-B (2) · Carmustine (1) · Data Collection (1) · Lomustine (1) · VBI-2900 COVID-19 vaccine (1)
Canada (6) · United States (4) · Belgium (2) · Finland (2) · Australia (1) · China (1) · Germany (1) · New Zealand (1) · Russia (1) · Singapore (1) · South Korea (1) · Thailand (1) · United Kingdom (1) · Vietnam (1)
William Cameron, MD (3) · Francisco Diaz-Mitoma, MD, PhD (2) · Do G Canh, MD (1) · Elena Esaulenko (1) · Francisco Diaz-Mitoma, MD (1) · Jacob Atsmon, MD (1) · Joanne Langley, MD (1) · Joanne M Langley, MD (1) · Xiaofei Chen (1)
PMID 33119068, PMID 33451780, PMID 33989539, PMID 34116873, PMID 34636914, PMID 37147201, PMID 38142214, PMID 39536477, PMID 40043858
2017 (2)